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Transcription of transposable elements interspersed in the genome is controlled by complex interactions between their regulatory
elementsandhostfactors.However,thesameregulatoryelementsmaybeoccasionallyusedforthetranscriptionofhostgenes.One
such example is the human L1 retrotransposon, which contains an antisense promoter (ASP) driving transcription into adjacent
genes yielding chimeric transcripts. We have characterized 49 chimeric mRNAs corresponding to sense and antisense strands of
human genes. Here we show that L1 ASP is capable of functioning as an alternative promoter, giving rise to a chimeric transcript
whose coding region is identical to the ORF of mRNA of the following genes: KIAA1797, CLCN5,a n dSLCO1A2. Furthermore,
in these cases the activity of L1 ASP is tissue-speciﬁc and may expand the expression pattern of the respective gene. The activity
of L1 ASP is tissue-speciﬁc also in cases where L1 ASP produces antisense RNAs complementary to COL11A1 and BOLL mRNAs.
Simultaneous assessment of the activity of L1 ASPs in multiple loci revealed the presence of L1 ASP-derived transcripts in all
human tissues examined. We also demonstrate that L1 ASP can act as a promoter in vivo and predict that it has a heterogeneous
transcriptioninitiationsite.OurdatasuggestthatL1ASP-driventranscriptionmayincreasethetranscriptionalﬂexibilityofseveral
human genes.
Copyright © 2006 Kert M¨ atlik et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Non-LTR and LTR retrotransposons are the two most abun-
dant classes of transposable elements that contain regula-
tory regions (promoter, enhancer, and polyadenylation sig-
nal) necessary for their transcription and transposition [9].
Although most of the non-LTR retrotransposons and all the
LTR retrotransposons in the human genome have lost their
transpositional competence due to broken ORFs, a large
number of them have retained regulatory sequences [10].
Scatteredalloverthechromosomes,retrotransposonscanaf-
fect the regulation of host genes’ transcription.
Recent studies carried out in several laboratories have
revealed that LTR retrotransposons, such as an intracister-
nal A-particle in mice [11], endogeneous retroviruses in hu-
mans and mice [12], and Wis 2-1A in wheat [13], can in-
ﬂuence transcription of adjacent genes. Similarly, two fami-
lies of non-LTR retrotransposons, L1 [3] and B2 SINE [14],
have been shown to drive transcription of human and mouse
genes, respectively. It has been shown that the eﬀect of retro-
transposons on the host gene expression depends on their
epigenetic status and thus may cause phenotypic variation
between genetically identical individuals [15].
Retrotransposons may provide alternative promoters for
hostgenes.Here,theknownexamplesincludeLTR-mediated
transcriptionofAgouti [16],PTN [17],apoC-I,EDNRB[18],
CYP19 [19], β3GAL-T5[20],andSPAMI genes[21].Wehave
previously shown that in transformed cells many human
genes are transcribed from the L1 ASPs located in introns of
these genes [2, 3].
To reveal the possible function of L1 ASP as an alterna-
tive promoter of human genes, we carried out a systematic
search for additional chimeric L1 ESTs/mRNAs deposited in
GenBank. Here we describe 49 chimeric mRNAs generated
byL1ASP-driventranscription.Fourofthesechimerasdiﬀer
from the bona ﬁde mRNAs by 5  untranslated region (UTR)
and another four (antisense RNAs) have regions comple-
mentary to exons of known mRNAs. Based on these bioin-
formatic data, we show that L1 ASP is capable of function-
ing as an alternative promoter in normal human tissues and
drives tissue-speciﬁc transcription of several human genes.
METHODS
Computationalanalysis
The search and analysis of chimeric L1 transcript sequences
derived from the human subset of EST division of GenBank,2 Journal of Biomedicine and Biotechnology
Table 1: Primers used for the detection of mRNAs, chimeric mRNAs, and L1 splice forms.
mRNA Forward primer Reverse primer Annealing temperature
AL711955 CTTGTGGCAGAAGGGAGAAG GCAGCAGAGAGGACTTTGG 65◦C
(L1) KIAA1797 TCTCAGACTGCTGTGCTA GCAGCAGAGAGGACTTTGG 60◦C
CLCN5 (uP) GGAGAAAACAGGGCCACATA CATGCTCAGAGTTCCAGCAA 60◦C
CLCN5 (dP) GACCCTTTTGTCTCCCTTCC CATGCTCAGAGTTCCAGCAA 60◦C
L1-CLCN5 CTGCTGTGCTAGCAATCAGC CATGCTCAGAGTTCCAGCAA 60◦C
SLCO1A2 AAAGCGTTCCAGGTATTTTTG GCTCTTCAGGGTGTTCCAAG 55◦C
L1-SLCO1A2 CTGCTGTGCTAGCAATCAGC GCTCTTCAGGGTGTTCCAAG 60◦C
MET ACGGTCCAAAGGGAAACTCT CCTTGTAGATTGCAGGCAGAC 60◦C
L1-MET-A CTGCTGTGCTAGCAATCAGC CCTTGTAGATTGCAGGCAGAC 60◦C
L1-MET-B CTAAGCAAGCCTGGGCAATG CCTTGTAGATTGCAGGCAGAC 60◦C
L1-MET-C TTCCCGGCTGCTTTGTTTAC CCTTGTAGATTGCAGGCAGAC 60◦C
L1-MET-D GGCTCCACCCAGTTCGAGCT CCTTGTAGATTGCAGGCAGAC 60◦C
L1-MET-E AGGCAGGCCTCCTTGAGCTCTG CCTTGTAGATTGCAGGCAGAC 60◦C
L1-MET-F AGGTGGAGCCTACAGAGGCAG CCTTGTAGATTGCAGGCAGAC 60◦C
L1-MET-G TGCAGAGGTTACTGCTGTCT CCTTGTAGATTGCAGGCAGAC 60◦C
COL11A1 GGATTTCAAGGCAAGACCG TTTGCACCTTCTTTTCCTGC 55◦C
L1-COL11A1 CTGCTGTGCTAGCAATCAGC TAGGGTGATCCAGGTCCTCA 60◦C
BOLL CGCAAACATCAAACCAGATG TACTGTGTGGTGGCCTGGTA 60◦C
L1-BOLL CTGCTGTGCTAGCAATCAGC GCCTTCAAATGCAGGACTGT 60◦C
L1 II sp v1 CTCCCCCAGCCTCGCTGC GGTTCATCTCACTGGCTC 60◦C
L1 IV sp v1 CTGCTGTGCTAGCAATCAGC GGTTCATCTCACTGGAAA 55◦C
1sp v stand for splice variant
EMBL, and DDBJ was carried out by using the strategy de-
scribed earlier [2]. The alignment of EST and mRNA se-
quences to genomic contigs was done with SPIDEY [1]a n d
conﬁrmedwiththehumangenomebrowseravailableatUni-
versity of California, Santa Cruz [5]. BLAST [6], BLAST2 se-
quences [7], and SPIDEY programs, used in the analysis of
sequences of RT-PCR products, were run on the National
Center for Biotechnology Information BLAST network ser-
vice using default parameters.
The Transcriptional start sites in the DBTSS [22]w e r e
mapped using the BLASTN [6]. The accession numbers
of the respective one-pass cDNA entries were OFR00417,
CNR02292, KAR05296, TDR09332, T3R04859, TDR07820,
KMR03236, HKR11044, KMR01202, COL02332, KMR-
02654, TDR05153, TDR04283, T3R08474, T3R07002, TDR-
08640, DMC04507, HKR03051, T7R06886, T3R04414,
29R05294,OFR01051,T3R00241,andHKR11121.Splicesite
search was done with NNSPLICE 0.9 [23]a n dN e t G e n e 2
[24].
RT-PCR,Southernblot,andsequenceanalysis
PCR ampliﬁcation of the human cDNAs of the multiple tis-
sue cDNA (MTC) panels I and II (BD Biosciences Clon-
tech)wascarriedoutusingrecombinantTaqpolymeraseand
Taq buﬀer with (NH4)2SO4,2 . 0m MM g 2Cl2,0 . 2m Md N T P
(Fermentas), and 0.75μM primers. Each reaction contained
0.5μl cDNA and 0.5 units of Taq polymerase in a ﬁnal vol-
ume of 10μl. After cDNA denaturation at 95◦Cf o r1m i n u t e ,
ampliﬁcation (35–40 cycles) was carried out by using the fol-
lowing cycling proﬁle: 95◦C3 0s ,5 5 ◦–65◦C3 0s ,a n d7 2 ◦C
30s for products < 0.5Kbor1minuteforproducts> 0.5Kb.
Primers and annealing temperatures used are given in the
supplementary table Table 1. The locations of primers are
shown in Figures 1 and 2. PCR products were sized on 1-2%
agarose gels and analyzed by restriction mapping. After gel
elution, their sequences were determined from both ends us-
ing BigDye Terminator cycle sequencing kit (Applied Biosys-
tems).
First strand L1-MET cDNA was synthesized with a re-
verse primer positioned in MET exon 5 (TATGGTCAGC-
CTTGTCCCTC) using total RNA isolated from human ter-
atocarcinoma cell line (NTera2D1) and RevertAid H minus
M-MuLV reverse transcriptase (Fermentas). This cDNA was
denatured at 95◦C for 1minute and ampliﬁed (30 cycles, see
above) using one of the primer pairs (L1-MET-A-G) shown
in Table 1. For Southern blot analysis, the RT-PCR products
obtained were sized on an agarose gel, transferred to a nylon
membrane and hybridized with a riboprobe speciﬁc to MET
exons 2–5. Hybridization-positive products were detected by
autoradiography.Kert M¨ atlik et al 3
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Figure 1: Distribution of chimeric mRNAs derived from the L1 ASP as an alternative promoter. The presence of native mRNAs derived from
a gene predicted by (a) AL711955 and KIAA1797,( b )CLCN5 [25], (c) SLCO1A2,( d )MET proto-oncogene [26], and their corresponding
chimeric transcripts is shown at the upper and lower RT-PCR panels. cDNAs were derived from the following human tissues: 1, thymus; 2,
prostate; 3, spleen, 4, small intestine; 5, colon; 6, ovary; 7, testis; 8, peripheral blood leukocytes; 9, placenta; 10, skeletal muscle; 11, brain;
12, kidney; 13, heart; 14, lung; 15, pancreas, and 16, liver. GenBank accession numbers for each mRNA and chimeric L1 mRNA are shown.
Product sizes are shown on the left of each panel and below the forward primer on the scheme. L1 (PA2 or Ta subfamily) is shown by a
l a r g eb o xw i t ht h e5   UTR region indicated in red and its orientation is marked by an arrow. Exons are marked by open boxes (not in scale).
Splicing schemes are shown by lines. The location of translation initiation, codon is marked by ATG. Primers used in PCR are shown by
arrowheads below the exons. (b) Exons transcribed from the CLCN5 upstream promoter [uP] are designated with −1a to −4 a. (c) A 315bp
RT-PCR product corresponds to L1-SLCO1A2 transcript derived from the upstream L1 ASP (L1 ASP2), but not from the L1 ASP (L1 ASP1)
predicted by the EST (BX955947). (d) A minor L1-MET splice variant is shown by a broken line. P stands for promoter and dP stands for
downstream promoter.
RESULTS
L1ASPispredictedtofunctionas
analternativepromoter
W eh a v ep r e v i o u s l yc h a r a c t e r i z e d9o u to f2 5E S T sr e p r e -
senting the L1 ASP-driven transcription of human genes [2].
Using the strategy described earlier [2] and an updated ver-
sion of the dbEST (12 May 2004), we extended our search to
reveal chimeric transcripts derived from an L1 ASP acting as
asole/alternativepromoterordrivingantisensetranscription
of host gene. Our search revealed 81 ESTs containing the op-
posite strand of L1 5  UTR, followed by a region identical
to a cellular mRNA or random genomic sequence. Of this
large number of chimeric transcripts, 49 ESTs represented
mRNAsderivedfromthegenesannotatedinRefSeqdatabase
[8] (see the supplementary table (Table 2)). The remaining
32 ESTs contained noncoding or repetitive DNA sequences
(Alus,MIR,LTR,L1,etc)splicedtotheL15  UTR.Sincethey
contained only short ORFs (< 100aa) and had no similarity
toknownproteins,asrevealedbyBLASTPanalysis,theywere
not analyzed further.4 Journal of Biomedicine and Biotechnology
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Figure 2: Distribution of antisense RNAs derived from L1 ASP. The presence of mRNAs derived from (a) COL11A1 [27], (b) BOLL [28],
and their antisense RNAs is shown at the upper and lower RT-PCR panels, respectively. The exons of antisense RNAs L1-COL11A1 and L1-
BOLL complementary to exon 40 of COL11A1 and exon 6 of BOLL are shown as grey boxes. (a) COL11A1 exons 38–47. (b) Two L1-BOLL
splice variants and a nonspeciﬁc product, marked by an asterisk, are presented. A 211bp product derived from the L1 ASP1 is identical to
EST BE866323 (splicing scheme III). A novel 242bp product generated from the L1 ASP2 corresponds to the splicing scheme V. For the
remaining description details, see Figure 1 legend.
Because of our interest in the L1 ASP-driven transcrip-
tion of human genes, we carried out a detailed analysis of
the 49 chimeric ESTs (Table 2). While most of the ESTs (40
out of 49) corresponded to mRNAs generated from the L1
ASPs of full-length L1s located in introns, 7 ESTs/mRNAs
(NM 017794, BP351387, BM557937, CF593264, BP358215,
BX955947, and BU176833) were derived from L1 ASPs lo-
cated upstream of genes. In these 7 cases, L1 ASP may
function as an alternative promoter. Four of these cases
(NM 017794, BP351387, BX955947, and BP358215) repre-
sented chimeric mRNAs that contained the ﬁrst coding exon
of the gene. Thus, their translation could produce proteins
identical to those encoded by the respective gene (Table 3).
These genes encoded hypothetical protein KIAA1797 (possi-
bly involved in mitotic chromosome condensation), CLCN5
(chloride channel 5) [25], SLCO1A2 (solute carrier organic
aniontransporterfamilymember1A2),andRGS6(regulator
ofG-proteinsignalling6)[29].FortheremainingthreeESTs,
splicing occurred within the coding sequence, giving rise to
the chimeric mRNA lacking bona ﬁde translation initiation
signals. Since translation initiation signals are commonly lo-
cated in the second exon of mammalian mRNAs [30], an
L1 ASP located in the ﬁrst intron could also give rise to
a translatable chimeric mRNA. Of the 3 ESTs (BM910612,
BE735854, and BP352155) derived from such L1 ASPs, only
one (BE735854) had translation initiation signals matching
those of the bona ﬁde mRNA.
Of the 49 ESTs/mRNAs analyzed, 45 chimeras matched
the orientation of the respective gene, while 4 ESTs had re-
gions complementary to the exons of known mRNAs and
thus were derived from the opposite strand of the gene
(Table 3).
Two of these ESTs (CB960713 and AV693621) were de-
rived from the L1 ASPs located in the intron 25 of ABCA9Kert M¨ atlik et al 5
Table 2: Widespread L1 ASP-driven transcription of human genes revealed from ESTs/mRNAs.
EST1 Source2
Similarity to L1
5 UTR opposite
strand3
Similarity to
known mRNA4
Location in the
genome5 Orientation6
Type I splicing (1 EST)
BU943355++ (4 ex) Pool of 40 cell line
polyA+
4–59 ≡ 592–647
(96%)
60–289 ≡ 762–990
(96%) L1PA3
AC007780
Arylsulfatase G,
NM 014960
331–649 ≡
1342–1660 (99%)
NT 010641 (chr 17)
10/11 Sense
Type II splicing (2 ESTs)
CD642260 (4 ex) Embryonic stem
cell line WA01/H1
12–117 ≡ 542–647
(97%)
118–230 ≡ 878–990
(96%) L1PA2
AC022762
Olfactory receptor,
family 56,
subfamily B,
member 4,
NM 001005181
373–728 ≡ 802–443
(98%)
NT 009237 (chr 11)
3 /1 Antisense
NM 017794 (46 ex)
RA-induced NT2
neuronal
precursor cells
4–150 ≡ 501–647
(93%)
151–262 ≡ 878–990
(93%) L1P
AL354879
Hypothetical
protein KIAA1797,
AL711955*
331–834 ≡ 60–563
(99%)
NT 008413 (chr 9)
5 /45 Sense
Type III splicing (22 ESTs)
BM910612 (6 ex)
Brain,
astrocytoma
grade IV cell line
1–134 ≡ 514–647
(98%) L1Ta (Hs)
AC011597
Fibronectin type III
domain containing
6 (cytokine
receptor),
NM 144717
268–915 ≡ 336–982
(98%)
NT 086641 (chr 3)
1/7 Sense
BF676152 (3 ex) Prostate
4–126 ≡ 520–647
(91%) L1PA2
AC097061
Hypothetical
protein BC014608,
NM 138796
127–713 ≡
422–1005 (91%)
NT 021877 (chr 1)
5/11 Sense
AU123136++ (7 ex) Uninduced NT2
cell line
1–125 ≡ 523–647
(96%) L1PA2
AC079005
Breast carcinoma
ampliﬁed sequence
3, NM 017679
126–623 ≡
710–1208 (99%)
NT 010783 (chr 17)
9/24 Sense
AA226814+ (3 ex)
Ntera-2
neuroepithelial
cells
1–111 ≡ 538–649
(93%) L1PA2
AC018470
Secernin 3
(dipeptidase),
NM 024583
112–347 ≡
843–1075 (96%)
NT 005403 (chr 2)
5/8 Sense
BU959632 (5 ex) Pool of 40 cell line
polyA+
4–45
.
= 606–647
L1Ta (Hs)
AC008496
Cardiomyopathy
associated 5,
NM 153610
46–559 ≡
3235–3748 (97%)
NT 006713 (chr 5)
8/12 Sense6 Journal of Biomedicine and Biotechnology
Table 2: Continued.
BF208095+ (6 ex)
Bladder
carcinoma cell
line
2–57 ≡ 592–647
(94%) L1PA2
AC002080
Hepatocyte growth
factor receptor
(MET
proto-oncogene),
NM 000245
132–456 ≡
1387–1714 (99%)
462–663 ≡
1805–2013 (92%)
NT 007927 (chr 7)
2/21 Sense
AA220950+ (3 ex)
Ntera-2
neuroepithelial
cells
1–39 ≡ 609–647
(89%) L1PA3
AC022261
Dynein,
cytoplasmic,
intermediate
polypeptide 1,
NM 004411
40–247 ≡ 613–818
(95%)
NT 007910 (chr 7)
5/17 Sense
BM557937 (7 ex)
Brain
astrocytoma
grade IV cell line
1–110 ≡ 538–647
(93%) L1PA3
AC022748
Cholinergic
receptor, nicotinic,
beta poly-peptide 4,
NM 000750
410–713 ≡ 168–471
(99%)
NT 024654 (chr 15)
5 /6 Sense
BG335812 (> 6e x )
Placenta
choriocarcinoma
cell line
2–105 ≡ 544–647
(93%) L1PA2
AC009949
Nuclear antigen
Sp100, NM 003113
106–522 ≡ 139–556
(90%)
NT 005403 (chr 2)
2/25 Sense
BE865812+ (4 ex)
Bladder
carcinoma cell
line
1–43 ≡ 605–647
(97%) L1Ta (Hs)
AL049838
Chromosome 14
open reading frame
37, NM 001001872
44–343 ≡ 933–1228
(96%)
NT 025892 (chr 14)
5/7 Sense
BE866323+ (4 ex)
Bladder
carcinoma cell
line
1–92 ≡ · 556–647
(96%) L1PA2
AC073058 L1PA2
AC020550
Bol, boule-like
(Drosophila),
NM 033030
145–204 ≡ 790–731
(98%)
NT 005246 (chr 2)
3 /11 Antisense
BP352155 (5 ex)
Well-
diﬀerentiated
squamous cell
carcinoma cell
line TE13
1–113 ≡ 535–647
(96%) L1PA2
AC004519
Hypothetical
protein FLJ31340,
BX346336*
114–490 ≡ 500–876
(98%)
NT 086723 (chr 7)
1/>5 Sense
BP351387 (5 ex)
Well-
diﬀerentiated
squamous cell
carcinoma cell
line TE13
1–67 = 581–647
L1Ta (Hs)
AL663118
Chloride channel 5,
NM 000084
213–583 = 243–613
NT 086939 (chr X)
5 /12 Sense
BP351082 (> 4e x )
Well-
diﬀerentiated
squamous cell
carcinoma cell
line TE13
1–71 ≡ 576–647
(95%) L1PA3
AC114734
Hypothetical
protein MGC16169
(protein kinase)
NM 033115
72–593 ≡
1913–2433 (99%)
NT 086651 (chr 4)
17/24 Sense
BP369881 (6 ex) Testis
1–65 ≡ 581–647
(92%) L1PA3
AL136525
WD repeat and
FYVE domain
containing 2,
NM 052950
66–570 ≡ 460–963
(99%)
NT 086801 (chr 13)
3/12 SenseKert M¨ atlik et al 7
Table 2: Continued.
AA226765 (3 ex)
Brain Ntera-2
neuroepithelial
cells
1–67 ≡ 581–647
(92%) L1PA3
AC025170
Hypothetical
protein FLJ35779,
NM 152408
68–356 ≡ 480–767
(97%)
NT 086677 (chr 5)
4/11 Sense
CF593264 (> 5e x ) P l a c e n t a
29–95 ≡ 581–647
(95%) L1PA3
AL050323
Phospholipase C,
beta 1, NM 182734
174–769 ≡
103–692 (98%)
NT 011387 (chr
20) 5 /33 Sense
BP873102 (5 ex)
Embryonal
kidney cell
line =“293”
1–67 ≡ 581–647
(95%) L1PA2
AL022400
RAB GTPase
activating protein
1-like, NM 014857
68–583 ≡
731–1244 (95%)
NT 086598 (chr 1)
4/21 Sense
CD110319 (2 ex)
Placenta
“preeclamptic
placenta”
25–92 ≡ 580–647
(97%) L1PA2
AC004452
FLJ16237 protein,
NM 001004320
93–568 ≡ 428–900
(97%)
NT 086703 (chr 7)
2/ 1 3 Sense
BX476029 (5 ex) Pooled from
diﬀerent tissues
2–77 ≡ 572–647
(93%) L1PA3
AL121946
Polycystic kidney
and hepatic disease
1, NM 138694
78–567 ≡
7273–7762 (99%)
NT 007592 (chr 6)
43/67 Sense
CB960713 (4 ex) Placenta
30–107 ≡ 570–647
(96%) L1PA3
AC005922
ATP-binding
cassette, subfamily
A, NM 172386
108–208 =
3283–3183
NT 010641 (chr
17) 25/38 Antisense
CD644604 (3 ex)
Embryonic stem
cells, cell
line =“WA01”
14–115 ≡ 547–647
(94%) L1PA3
AC022029
Catenin (cadherin-
associated protein),
alpha 3,
NM 013266
116–736 ≡
755–1375 (98%)
NT 086771 (chr
10) 5/19 Sense
Type IV splicing (1 EST)
CF594290 (9 ex) Placenta
29–230 ≡ 531–732
(94%)
231–340 ≡ 878–988
(95%) L1PA2
AC022306
Hypothetical
protein FLJ32800,
NM 152647
354–451 =
1305–1402
452–780 ≡
1642–1964 (97%)
NT 010194 (chr
15) 5/16 Sense
Type V splicing (19 ESTs)
BE787024++ (3 ex)
Lung large cell
carcinoma cell
line
17–215 ≡ 533–732
(98%) L1Ta (Hs)
AC079750
Activin A receptor,
type IC,
NM 145259
216–752 ≡
548–1086 (95%)
NT 005403 (chr 2)
2/9 Sense
BE568884+ (4 ex)
Bladder
carcinoma cell
line
1–178 ≡ 554–732
(97%)
CD96 antigen,
NM 005816
179–627 ≡
659–1113 (97%)
NT 086640 (chr 3)
2/15 Sense8 Journal of Biomedicine and Biotechnology
Table 2: Continued.
BE617461++ (6 ex)
Colon
adenocarcinoma
cell line
8–185 ≡ 553–732
(98%) L1PA2
AC092916
RAB3A interacting
protein,
NM 175625
186–738 ≡
998–1556 (98%)
NT 086796 (chr
12) 3/10 Sense
BE568818+ (3 ex)
Bladder
carcinoma cell
line
1–163 ≡ 570–732
(93%) L1PA2
AC010585
Secretory carrier
membrane protein
1, NM 052822
164–516 ≡
717–1063 (97%)
NT 006713 (chr 5)
6/8 Sense
BU858570 (2 ex) Pool of 40 cell line
polyA+ RNAs
4–166 ≡ 571–732
(93%) L1PA2
AL691464
Guanylate binding
protein 1,
NM 002053
167–402 ≡
259–494 (95%)
NT 004686 (chr 1)
2/11 Sense
BF028725 (3 ex)
Bladder
carcinoma cell
line
2–123 ≡ 612–732
(91%) L1PA2
AC004800
Hypothetical
protein FLJ36166,
NM 182634
124–264 ≡
3282–3424 (95%)
NT 086704 (chr 7)
2/21 Sense
AA224229+ (4 ex)
6w e e k ,
diﬀerentiated,
post-mitotic hNT,
neurons
1–94 ≡ 640–732
(98%) L1Ta (Hs)
AL365308
Chromosome 6
open reading frame
170, NM 152730
95–430 ≡
2622–2957 (99%)
NT 086697 (chr 6)
22/30 Sense
BG542212++ (> 3 ex) Lung
2–187 ≡ 547–732
(97%) L1Ta (Hs)
AC096569
Zinc ﬁnger protein
638, NM 014497
188–638 ≡
3576–4013 (92%)
NT 022184 (chr 2)
18/28 Sense
AV693621 (2 ex) Hepatocellular
carcinoma
1–172 ≡ 559–732
(93%) L1PA2
AL627203
Collagen, type XI,
alpha 1, variant A,
NM 001854
187–279 =
3433–3341
NT 004623 (chr 1)
46/67 Antisense
BE735854+ (6 ex)
Pancreas
adenocarcinoma
cell line
1–95 ≡ 638–732
(93%) L1PA2
AC092903
Similar to beta-1, 4-
mannosyltransferase,
CD708577*
95–387 ≡ 174–466
(99%)
NT 005588 (chr 3)
1/>5 Sense
R64632 (4 ex) Soares placenta
Nb2HP
1–52 = 681–732
L1PA2 AL713859
Hypothetical
protein FLJ10986,
NM 018291
53–406 ≡
1319–1671 (98%)
NT 029223 (chr 1)
11/14 Sense
BP352672 (4 ex)
Well-
diﬀerentiated
squamous cell
carcinoma cell
line TE13
1–126 ≡ 608–732
(94%) L1PA2
AL354711
Chromosome 9
open reading frame
39, NM 017738
127–603 =
152–631
NT 008413 (chr 9)
2/23 Sense
BP358215 (7 ex)
Mammary gland
tumor cell line
T47D
1–147 ≡ 586–732
(92%) L1PA2
AL391749
Regulator of
G-protein
signalling 6,
NM 004296
148–581 ≡
188–621 (99%)
NT 026437 (chr
14) 5 /17 SenseKert M¨ atlik et al 9
Table 2: Continued.
H72033 (4 ex) Soares breast
2NbHBst
1–107 ≡ 626–732
(97%) L1PA2
AC079005
Breast carcinoma
ampliﬁed sequence
3, NM 017679
108–370 ≡
710–967 (95%)
NT 010783 (chr
17) 9/24 Sense
CA488981 (3 ex)
Cell line=ZR-75-
1, MCF7,
SK-BR-3,
MDA-MB-231,
hTERT-HME1,
LNCaP
1–159 ≡ 574–732
(91%) L1PA2
AC034215
Monogenic,
audiogenic seizure
susceptibility 1
homolog,
NM 032119
160–736 ≡
17956–18532
(99%)
NT 086677 (chr
5) 83/98 Sense
BX955947 (3 ex) Pooled from
diﬀerent tissues
1–116 ≡ 617–732
(89%) L1PA2
AC006559
Solute carrier
organic anion
transporter family,
member 1A2,
NM 021094
240–342 =
186–288
NT 009714 (chr
12) 5 /14 Sense
BX477512++ (3 ex) Pooled from
diﬀerent tissues
2–129 ≡ 605–732
(93%) L1PA2
AC024061
Hypothetical
protein FLJ38736,
NM 182758
130–551 =
3191–3216
NT 086827 (chr
15) 18/20 Sense
CN412489++ (2 ex)
Embryonic stem
cells, embryoid
bodies from H1, 7
and H9 cell lines
1–151 ≡ 582–732
(98%) L1PA2
AL133299
FLJ46156 protein,
NM 198499
152–348 =
1087–1283
NT 086806 (chr
14) 8/37 Sense
CN408255 (4 ex)
Embryonic stem
cells,
DMSO-treated
H9 cell line
1–180 ≡ 553–732
(95%) L1PA2
AP00942
Baculoviral IAP
repeat-containing
2, NM 001166
181–514 =
2766–3099
NT 033899 (chr
11) 6/9 Sense
Type VI splicing (4 ESTs)
CD643062 (8 ex) Embryonic stem
cell line WA01/H1
10–220 ≡ 780–990
(97%) L1PA2
AC018741
Hypothetical
LOC388927,
XM 371478
237–744 ≡ 1–509
(99%)
NT 015926 (chr
2) ND Sense
BU176833 (6 ex)
Eye
retinoblastoma
cell line
1–227 ≡ 763–989
(96%) L1PA3
AC105054
Rho GTPase
activating protein
25, NM 014882
536–878 ≡
419–757 (97%)
NT 022184 (chr
2) 5 /10 Sense
BE568192 (3 ex)
Bladder
carcinoma cell
line
1–60 ≡ 931–990
(98%) L1PA2
AP005264
Similar to
hypothetical
protein
LOC375127,
XM 496265
95–367 ≡ 213–490
(95%)
NT 010859 (chr
18) 3/5 Sense10 Journal of Biomedicine and Biotechnology
Table 2: Continued.
BP245205 (3 ex)
Embryonal
kidney cell line
293
6–135 ≡ 861–990
(95%) L1PA2
AC099512
Monogenic,
audiogenic seizure
susceptibility 1
homolog,
NM 032119
138–574 ≡
17953–18384
(98%)
NT 086677 (chr
5) 91/98 Sense
1 EST/mRNA GenBank accession number and number of exons (ex) determined by SPIDEY [1]. ESTs are grouped according to 6 diﬀerent
splicing schemes [2]. Sixteen identical or similar ESTs described earlier by Nigumann et al [2] and Wheelan et al [44]a r es h o w nb y+ and
++,r e s p e c t i v e l y .
2 Source of the EST as annotated in EST division of GenBank.
3 EST similarity (≡) or identity (=) to a representative L1 genomic clone #11A [3]. Subfamily of L1 [4] and GenBank accession number were
determined by genome browser [5] .F o rs o m eE S T st h e5   nucleotides (< 28nt) were derived either from vector/adaptor or represented as
low quality sequence.
4 Similarity/identity to known mRNA as determined by BLASTN [6] and BLAST2 sequences [7] programs. mRNA description is based on
the RefSeq database [8]. If the mRNA has not been described, an EST (marked by an asterisk) is shown. This EST contains a putative ﬁrst
exon transcribed from the non-L1 (native) promoter.
5 Genomic contig (accession no), chromosome (chr), and position of the L1 ASP in the intron, upstream (5 ) or downstream (3 )/total
number of exons, as determined with MegaBLAST and SPIDEY programs. ND stands for not determined.
6 Orientation with respect to the gene’s transcription.
(ATP-binding cassette, subfamily A, member 9) [31] and in-
tron 46 of COL11A1 (collagen type XI alpha 1) [27], respec-
tively (Table 3). The remaining two ESTs (CD642260 and
BE866323) were derived from L1 ASPs located downstream
of the gene. One of these L1 ASPs resided 77Kb downstream
of the single exon gene encoding olfactory receptor, family
56, subfamily B, member 4 (OR56B4)[ 32] and the other lo-
c a t e d3 4K bd o w n s t r e a mo fBOLL, homologous to the bol or
boule-like gene of Drosophila [28].
L1ASPprovidesanalternativepromoterfor
severalhumangenes
To reveal the potential of L1 ASP to function as an alterna-
tive promoter, we determined the expression proﬁle of the
chimeric mRNAs (containing bona ﬁde translation initia-
tion signals) in 16 diﬀerent human tissues. For comparison,
we also determined transcription from the native promoters
(genes’ true promoters). Results for the three chimeric mR-
NAs (KIAA1797,L 1 - CLCN5,a n dL 1 - SLCO1A2)w h i c hw e r e
detected in the tissues studied are presented in the following
section.
Figure 1(a) shows that both the chimeric KIAA1797
mRNA, derived from the L1 ASP located about 26Kb up-
stream of the ﬁrst exon of gene, and the native mRNA (the
5  end of the mRNA was predicted from EST AL711955) are
expressed in lung and pancreas. In addition, native mRNA is
expressed in testis, placenta, and liver.
Figure 1(b) shows that the chimeric L1-CLCN5 mRNA
is expressed exclusively in placenta, while CLCN5 mRNAs
derived from the upstream and downstream promoters (lo-
cated about 102Kb and 44Kb from the L1 ASP, resp) pro-
duce mRNAs expressed strongly in lung. Translation of the
chimeric mRNA could yield a protein identical to the one
obtained from the CLCN5 mRNA derived from the down-
stream promoter. However, the latter is inactive in placenta
suggesting that the L1 ASP provides placenta-speciﬁc expres-
sion to one of the protein isoforms encoded by CLCN5.T h e
other protein isoform has a 70 aa-long N-terminal extension
and is derived from an mRNA generated from the CLCN5
upstream promoter. This promoter is active in a number of
tissues.
Figure 1(c) shows that the chimeric L1-SLCO1A2 mRNA
predicted from the EST (BX955947) is derived from the L1
ASP located 61Kb upstream of the SLCO1A2 ﬁrst exon. Sur-
prisingly, RT-PCR yielded a 315bp product (instead of the
expected 324bp product) derived from another L1 ASP lo-
cated about 24Kb further upstream. This novel chimeric
mRNA is expressed exclusively in placenta, while SLCO1A2
mRNA is present in a number of tissues, but not in placenta.
Therefore, similarl to CLCN5, L1 ASP is responsible for the
placenta-speciﬁc expression of SLCO1A2.
Since the multiple tissue cDNA panel has been pro-
duced using diﬀerent donors for diﬀerent tissues (brain and
lung pooled from 2 donors and other tissues pooled from
4–45 donors, except leukocytes which were pooled from 550
donors; the total number of donors was ∼750), it is conceiv-
able that an RT-PCR product represents a donor-speciﬁc L1
insertion rather than tissue speciﬁc activity of the L1 ASP in
that chromosomal position. Sequence analysis showed that
only one of the L1 elements (L1-CLCN5), for which the
tissue-speciﬁcity of L1 ASP activity was examined (Figures
1 and 2), belongs to the highly polymorphic L1Ta subfamily
[33]. The rest of the L1 elements, depicted in Figures 1 and
2, belong to the L1PA2 subfamily that expanded before the
divergence of hominids [34], although some polymorphic
insertions have been reported in humans [35]. It is unlikely
that an L1 insertion is found in only one of the ∼750 donorsKert M¨ atlik et al 11
Table 3: Examples of the L1 ASP functioning as an alternative promoter or driving antisense transcription of human genes.
EST1 Source2
Similarity to L1
5 UTR opposite
strand3
Similarity to
known mRNA4
L o c a t i o ni nt h e
genome5 Orientation6
Type II splicing
CD642260
(4 ex)
Embryonic stem
cell line WA01/H1
12–117 ≡ 542–647
(97%)
118–230 ≡ 878–990
(96%) L1PA2
AC022762
Olfactory receptor,
family 56, subfamily
B, member 4,
NM 001005181
373–728 ≡ 802–443
(98%)
NT 009237 (chr 11)
3 /1 Antisense
NM 017794
(46 ex)
RA-induced NT2
neuronal precursor
cells
4–150 ≡ 501–647
(93%)
151–262 ≡ 878–990
(93%) L1P AL354879
Hypothetical protein
KIAA1797,
AL711955∗
331–834 ≡ 60–563
(99%)
NT 008413 (chr 9)
5 /45 Sense
Type III splicing
BE866323+
(4 ex)
Bladder carcinoma
cell line
1–92 ≡ · 556–647
(96%) L1PA2
AC073058 L1PA2
AC020550
Bol, boule-like
(Drosophila),
NM 033030
145–204 ≡ 790–731
(98%)
NT 005246 (chr 2)
3 /11 Antisense
BP351387
(5 ex)
Well-diﬀerentiated
squamous cell
carcinoma cell line
TE13
1–67 = 581–647
L1Ta (Hs) AL663118
Chloride channel 5,
NM 000084
213–583 = 243–613
NT 086939 (chr X)
5 /12 Sense
CB960713
(4 ex) Placenta
30–107 ≡ 570–647
(96%) L1PA3
AC005922
ATP-binding cassette,
subfamily A,
NM 172386
108–208 =
3283–3183
NT 010641 (chr 17)
25/38 Antisense
Type V splicing
AV693621
(2 ex)
Hepatocellular
carcinoma
1–172 ≡ 559–732
(93%) L1PA2
AL627203
Collagen, type XI,
alpha 1, variant A,
NM 001854
187–279 =
3433–3341
NT 004623 (chr 1)
46/67 Antisense
BP358215
(7ex)
Mammary gland
tumor cell line
T47D
1–147 ≡ 586–732
(92%) L1PA2
AL391749
Regulator of
G-protein signalling
6, NM 004296
148–581 ≡ 188–621
(99%)
NT 026437 (chr 14)
5 /17 Sense12 Journal of Biomedicine and Biotechnology
Table 3: Continued.
BX955947
(3 ex)
Pooled from
diﬀerent tissues
1–116 ≡ 617–732
(89%) L1PA2
AC006559
Solute carrier organic
anion transporter
family, member 1A2,
NM 021094
240–342 = 186–288
NT 009714 (chr 12)
5 /14 Sense
1 EST/mRNA GenBank accession number and number of exons (ex) determined by SPIDEY [1]. ESTs are grouped according splicing
schemes [2]. EST described earlier by Nigumann et al [2]i sm a r k e db y+.
2 Source of the EST as annotated in EST division of GenBank.
3 EST similarity (≡) or identity (=) to a representative L1 genomic clone #11A [3]. Subfamily of L1 [4] and GenBank accession number were
determined by genome browser [5]. For some ESTs, the 5  nucleotides (< 28nt) were either derived from vector/adaptor or represented as
low quality sequence.
4 Similarity/identity to known mRNA as determined by BLASTN [6] and BLAST2 sequences [7] programs. mRNA description is based on
the RefSeq database [8]. If the mRNA has not been described, an EST (marked by an asterisk) is shown. This EST contains a putative ﬁrst
exon transcribed from the non-L1 (native) promoter.
5 Genomic contig (accession no), chromosome (chr), and position of the L1 ASP in the intron, upstream (5 ), or downstream (3 )/total
number of exons, as determined with MegaBLAST and SPIDEY programs. ND stands for not determined.
6 Orientation with respect to the gene’s transcription.
represented in the MTC panel while it is present in GenBank
(Table 3) and Ntera2D1 cell line (data not shown). There-
fore we believe that the RT-PCR products obtained represent
tissue-speciﬁc L1 ASP activity of ﬁxed or high frequency L1
insertions.
In summary, the examples analyzed here provide evi-
dence that L1 ASP can function as an alternative promoter
in normal human tissues. Our results show that the L1 ASP-
driven transcription correlates with that of the respective
native promoter (Figure 1(a)) or expands the tissue-speciﬁc
expression pattern of the respective gene (Figures 1(b) and
1(c)).
Although our primary goal was to reveal the potential of
L1 ASP as an alternative promoter that generates translatable
mRNAs, we also determined the distribution of the chimeric
L1-MET mRNA derived from the L1 ASP located in the sec-
ond intron of the MET proto-oncogene [26]. Figure 1(d)
shows that the expression of the chimeric L1-MET mRNA
correlates with that of the MET mRNA.
L1ASPgeneratesantisensetranscripts
complementarytodifferentmRNAs
Of the 49 chimeric ESTs analyzed, only four corresponded
to mRNAs that contained regions complementary to the ex-
ons of known mRNAs (see above). The expression data are
presented for only those two so-called antisense RNAs which
were detected in the human tissues examined.
Figure 2(a) shows that the chimeric L1-COL11A1
mRNA, derived from the L1 ASP located in the intron 46 of
COL11A1, is expressed in testis and to a lesser extent in pla-
centa. Similarly, COL11A11mRNAispresentinthesetissues.
It should be noted that L1-COL11A1 (EST: AV693621) con-
tains a 90nt region complementary to the entire exon 40 of
COL11A1 (Table 3).
Figure 2(b) shows that two alternatively spliced variants
of the chimeric L1-BOLL, derived from the L1 ASPs located
a b o u t3 4K ba n d8 7K bd o w n s t r e a mo fBOLL, are expressed
inprostateandperipheralbloodleukocytes,respectively.The
5  ends of these transcripts are spliced according to splicing
schemes III and V [2]. BOLL mRNA is expressed exclusively
in testis. L1-BOLL contains a 60nt region complementary to
the 3  part of exon 6 of BOLL (Table 3). These results sug-
gest that L1 ASP-driven antisense transcription has no gen-
eral correlation with the transcription of the host gene.
L1ASP-derivedtranscriptsarepresentin
allhumantissuesexamined
Our study revealed that chimeric transcripts derived from
the six unique genomic regions are present only in a few
tissues. To examine the tissue speciﬁcity of L1 ASP activ-
ity more generally, we studied tissue-speciﬁc distribution of
L1 ASP-derived transcripts, in which splicing occurs within
the L1 5  UTR (splice variants II and IV) [2]. The use of
these splice variants allowed us to discriminate between the
L1 ASP-derived spliced transcripts and transcripts passing
through the whole L1 5  UTR. Figure 3 shows that the splice
variant II is expressed in most human tissues, except in thy-
mus,skeletalmuscle,andbrain.ThevariantIVshowsamore
uniform expression pattern with minimal expression in pla-
centa, skeletal muscle, and brain. In summary, these results
show that L1 ASP-derived transcripts are present in all hu-
man tissues examined.
L1ASP-driventranscriptionischaracterizedby
heterogeneousstartsite
The fact that the sequence corresponding to the opposite
strand of L1 5  UTR is present in the EST or mRNA se-
quence (Table 2) does not necessarily mean that transcrip-
tionisinitiatedintheL1ASPregion,thatis,intheL15  UTR
around positions +400 to +600 [3]. In order to ﬁnd evidence
that the L1 ASP region acts as a promoter in vivo, we ana-
lyzed the database of transcriptional start sites (DBTSS) [22]
for the presence of transcriptional start sites (TSS) whichKert M¨ atlik et al 13
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Figure 3: Distribution of L1 splice variants II and IV. The presence of splice variants was estimated by RT-PCR in 16 normal human tissues
(numberedasinFigure 1legend)usingareverseprimerdesignedtohybridizetothejunctionofexons1and2.Theschematicallyrepresented
splice variants II and IV use a common splicing acceptor site at position +116 and splicing donor sites located at positions +262 and +347,
respectively [2]. SP stands for L1 sense promoter; sp v stands for splice variant.
601 TCTGCAGAGGTTACTGCTG
G |
TCTT TTTGTTTGTCTGTGCCCTGCCCCCAGAG
550 GTGGAGCCTACAGAGG
F |
CAGGCAGGCCTCCTTGAGCT
E |
GTGGTGGGCTCCACC
499 CAGTTCGA
D |
GCTT CCCGGCTGCTTTGTT
C |
TACC TAAGCAAGC CTGGGCA
B |
ATGG
448 CGGGCGCCCCTCCCCCAGCCTCGTTGCCGCCTTGCAGTTTGATCTCAGACT
397 GCTGTGCTA GCAATC
A |
AGCGGGACTCCGTGGGCGTAGGACCCTCCGAGCCAG
(a)
ABCDE F G
1000bp
500bp
(b)
Figure 4: TSS mapped to the L1 ASP region. (a) The position of TSS present in the DBTSS is shown highlighted on the consensus sequence
of L1Hs [4] between positions 347 and 601. TSS with single and multiple entries present in the database are represented by yellow and blue
highlight, respectively. The letters above the sequence mark the 3  end of the oligonucleotide primers used in RT-PCR (see Table 1). (b)
Southern blot RT-PCR analysis of the L1-MET transcripts. The lanes are marked according to the primers used in the PCR. Multiple bands
on each lane represented the diﬀerent splice variants of the L1-MET transcript, as conﬁrmed by sequence analysis.
map to the opposite strand of L1 5  UTR. It has been esti-
mated that more than 80% of the TSS in the DBTSS repre-
sent true sites of transcription initiation, that is, they corre-
spond to the full-length cDNAs [36]. Twenty four of the 34
TSS, which mapped to the opposite strand of the L1 5  UTR,
resided between positions +386 and +503 (Figure 4(a)). The
observed nonuniform distribution of the TSS (∼70% of TSS
within ∼13% of the 5  UTR) clearly shows that the region
from +386 to +503, overlapping with the L1 ASP region,
must contain a promoter. These results also suggest that
transcription initiates at various positions within the L1 ASP
region (Figure 4(a)).
To conﬁrm the transcription initiation in the L1 ASP
region, we analyzed the distribution of L1-MET chimeric14 Journal of Biomedicine and Biotechnology
transcripts (Figure 1(d)) by using RT-PCR and various
oligonucleotide primers. Figure 4(b) shows that ampliﬁca-
tion of L1-MET cDNA can be carried out using primers A–F,
but not by using primer G. This result indicates that the TSS
is located in the L1 ASP region between the binding sites of
primers A and F, while the region corresponding to primer
Gi sa b s e n tf r o mt h eL 1 - MET transcripts. Also, an in silico
search for potential splicing signals [23, 24] did not reveal
any acceptor sites in the region between primers G and E,
lending support to the conclusion that transcription is initi-
ated in the L1 ASP region rather than read through the L1
5  UTR. The diﬀerence in band intensities (Figure 4(b))o b -
served for diﬀerent primer pairs is consistent with the pre-
dicted start site heterogeneity. In summary, our results show
that the L1 ASP can act as a promoter in vivo and its activity
is characterized by start site heterogeneity.
DISCUSSION
In this paper we show that L1 ASP can cause widespread
transcription of human genes and its activity correlates with
thatofthenativepromoterinsomecases,whileinothercases
it can expand the tissue-speciﬁc expression pattern of the re-
spective gene. It is believed that two or more genes located
in a single expression domain are coexpressed [37]. Accord-
ingly, an L1 ASP located near or within a gene may behave
like a “parasite” whose activity is dependent on the tran-
scriptionofthegene.Thisisexempliﬁedbythesimultaneous
transcription from the L1 ASP and native promoter (Figures
1(a), 1(d),a n d2(a)). Surprisingly, in other cases the L1 ASP
activity may be regulated independently, as observed here
forL1-CLCN5,L1-SLCO1A2,andL1-BOLLmRNAs(Figures
1(b),1(c),and2(b)).AlthoughtheL1ASP-driventranscripts
were detected in all tissues examined (Figure 3), the results
described suggest that the L1 ASPs at deﬁned loci are not
active in all tissues. The diﬀerent tissue-speciﬁc activity of
L1 ASPs can hardly be explained by their minimal sequence
divergence, but could be explained with diﬀerences in their
epigenetic state. In some cases, transcriptionally active epi-
genetic state could be stochastically conﬁned to some L1s in
certain tissues.
Our results show that L1 ASP acts as an alternative pro-
moter of several human genes (Figures 1(a)–1(c)). Alterna-
tive promoters, giving rise to alternative ﬁrst exons, gener-
ate variation in gene expression by increasing transcriptional
ﬂexibility and translational diversity. For example, the hu-
man NOS1 gene, encoding neuronal isoform of nitric ox-
ide synthase, has 9 alternative promoters, which determine
its tissue-speciﬁc transcription and translational eﬃciency
of the resulting NOS1 mRNAs with diﬀerent 5  UTRs [38].
Another striking example is the human BDNF gene, encod-
ing brain-derived neurotrophic factor, which has 6 promot-
ers and ﬁrst noncoding exons diﬀerentially used in diﬀerent
parts of the brain (A Kazantseva and T Timmusk, personal
communication). The L1 ASP, acting as an alternative pro-
moter, generates a chimeric mRNA whose translation could
produce a protein identical to the genuine protein. However,
the translatability of this transcript depends on the length of
the 5  UTR, the number of upstream ORFs, and the strength
of initiation signals [39]. Comparison between the 5  UTRs
of the native and chimeric mRNA revealed no major diﬀer-
ences in the above-mentioned factors that can abrogate the
usage of the genuine ORF (data not shown). Therefore, it is
likely that the chimeric L1 transcripts may be translated with
eﬃciency comparable to that of the native transcripts.
Alternative promoters can also generate mRNAs with
diﬀerent 5  coding exons, which may be used in the gen-
eration of N-terminal variants of the same protein [40].
Similarly, most L1 ASPs located in introns may, in princi-
ple, produce chimeric mRNAs and their translation could
yield N-terminally truncated proteins. However, transcrip-
tion from an L1 ASP located in an intron (39 examples de-
scribed in Table 2) may be strongly inhibited because of the
readthrough transcription from the upstream native pro-
moter [41, 42]. In addition, if transcripts from the intronic
L1 ASPs are produced, they may not be readily translated
because of the absence of proper initiation context. Al-
though N-terminally truncated proteins with possible dom-
inant negative eﬀects have been shown to exist in normal
and cancer cells [40] (references therein), additional exper-
iments are required to prove the translation of chimeric L1
transcripts.
We have detected two L1 ASP-derived antisense RNAs
complementary to the exons of COL11A1 and BOLL mR-
NAs (Figure 2). The other two antisense RNAs predicted
from the ESTs (Table 3) were not detected in the human
tissues analyzed. Antisense RNAs and antisense transcrip-
tion are known to cause downregulation of gene transcripts
via RNAi-mediated mRNA degradation [43] and transcrip-
tional collision [42], respectively. The possible regulatory in-
teraction between sense and antisense RNAs or transcription
may be revealed from the negative (or inverse) correlation
of their expression. The partial positive correlation between
COL11A1 mRNA and its antisense counterpart and the neg-
ative correlation between BOLL and L1-BOLL suggest that
there is no general correlation between the L1 ASP-driven
antisense transcription and the transcription of the gene.
In summary, we have demonstrated that L1 ASP is active
in a wide variety of normal human tissues and it is capable
of functioning as an alternative promoter by providing the
tissue-speciﬁc expression of several human genes.
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